Sandoz, a major maker of generic and copycat biologic drugs, reported $3.01 billion in sales for the first half of 2026 — up 9% from a year earlier and slightly above what analysts predicted (WHBL). The company released its full Half-Year Report 2026 on 5 August 2026 in Basel, alongside a press release titled "Sandoz delivers strong H1 2026 results, with outstanding biosimilar growth in second quarter" (Sandoz).

So what is a biosimilar? Some of the most expensive drugs in the world are called biologics — medicines made from living cells rather than simple chemicals. When the patent on a biologic expires, other companies can make a highly similar version, called a biosimilar, and sell it for less. Think of it like a store-brand version of a name-brand drug, but for a much more complex type of medicine.

The big story in Sandoz's results is that these biosimilar drugs are driving the company's growth. Sandoz said its second-quarter performance came from its biosimilar portfolio, though it did not publish a separate revenue figure just for that category. The 9% sales increase matters more when you consider that back in February, management told investors to expect faster growth in 2026 thanks partly to recently launched biosimilar products (Sandoz, via EQS News).

That February guidance, issued with the full-year 2025 results on 25 February 2026, set 2026 up as the year when new biosimilar launches would start paying off in actual sales. The first-half numbers are the first real evidence that this is happening. Whether the second half of the year keeps up the pace will depend on how many patients switch to the new drugs and whether regulators approve them for wider use.

On the regulatory front, the European Commission granted approval for Sandoz's biosimilar Bysumlog® (Sandoz Investors). This adds another product to Sandoz's European lineup and fits the growth story management has been telling. EU approval is important because it opens the door to reimbursement negotiations — the process of getting national health systems or insurers to pay for the drug. That process typically takes several months, so the revenue does not arrive immediately.

Sandoz's calendar is now busy. A Capital Markets Day — an event where company leaders present their strategy to investors and analysts — is set for 8 September 2026 in London. Management will likely face questions about how deep their biosimilar pipeline runs, how prices are holding up in key markets, and whether the strong first half means they should raise their full-year expectations (Sandoz Investors). A nine-month sales update follows on 28 October 2026 in Basel, giving a check on whether the second quarter's momentum carried into the third (Sandoz Investors). Full-year 2026 results are scheduled for 17 February 2027, also in Basel (Sandoz Investors).

The timing matters. There are only six weeks between today's report and the September event, leaving analysts little time to dig into the numbers before hearing directly from management. That puts pressure on the half-year report itself to be clear and detailed, especially on how profitable the biosimilar business is and what competition looks like in the US market.

In my view, the key question for anyone following Sandoz is whether this growth is built to last. Growth driven by selling more drugs — volume growth — tends to compound and stick around. Growth driven by charging higher prices can erode quickly in biosimilars, because competitors enter the market and push prices down. The half-year report and the September event should help investors tell the difference.